Trial Profile
A pilot safety and feasibility study of concurrent capecitabine (Xeloda) and external beam irradiation in the adjuvant treatment of high risk early stage breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Adverse reactions
- 18 Jul 2019 Status changed from active, no longer recruiting to completed.
- 30 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Dec 2008 Planned end date (1 Sep 2009) added as reported by ClinicalTrials.gov.